IRVINE, Calif.--(BUSINESS WIRE)--Mobix Labs, Inc. (NASDAQ: MOBX), a leading innovator of advanced connectivity and electromagnetic interference (EMI) filtering technology, today announced significant quarter-over-quarter revenue growth in its filter and interconnect products, powered by strong customer demand and major wins across mission-critical defense and aerospace programs. Mobix Labs Reports Sharp Increase in Filter Connector Orders Mobix Labs' wholly owned subsidiary, EMI Filter Solution.

MELVILLE, N.Y. and NEW YORK , July 17, 2025 /PRNewswire/ -- SupplyHouse (or, the "Company"), a leading pure-play e-commerce platform for the distribution of HVAC, plumbing, and electrical products, and KKR, a leading global investment firm, announced the formation of a strategic partnership to support the Company's long-term growth strategy.

INCHEON, Korea--(BUSINESS WIRE)-- #biosimilars--Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced today that the company has entered into a license, development and commercialization agreement (DCA) with Harrow (Nasdaq: HROW), for Samsung Bioepis' ophthalmology portfolio — BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTISi (ranibizumab) and OPUVIZ™ (aflibercept-yszy), a biosimilar referencing EYLEAii (aflibercept) — in the United States. The commercial license will become effective upon com.

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced it has received CE certification under the European Union (EU)'s In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR) for its germline next-generation sequencing (NGS) system, which includes FulgentExome and Fulgent Pipeline Manager (PLM). Based on available i.

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A601, the Company's investigational adeno-associated virus (AAV)-based gene therapy for the treatment of PKP2-arrhythmogenic cardiom.

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2025. “Based on the FDA's requirement f.

PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe presentation of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster). The new prefilled syringe removes the need to reconstitute separate vials prior to administration, simplifying the vaccine administration process for healthcare professionals. The existing vaccine presentation consists of two vials, a.

NASHVILLE--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter “Samsung Bioepis”) to secure the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab), and OPUVIZ™ (aflibercept-yszy), an FDA-approved biosimilar refer.

OVERLAND PARK, Kan.--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) (the “Company”), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare services platform, today announced the expanded launch of their innovative concierge-like service designed to specifically improve medication adherence for Medicare beneficiaries managing multiple chronic conditions and complex medication regimens. SelectQuote's SelectRx pharmacy recently trialed a new approach with.

Announces Second Quarter 2025 Earnings Release and Conference Call Schedule HOUSTON , July 17, 2025 /PRNewswire/ -- Main Street Capital Corporation (NYSE: MAIN) ("Main Street" or the "Company") is pleased to announce its preliminary operating results for the second quarter of 2025 and its second quarter 2025 earnings release and conference call schedule. In commenting on the Company's preliminary operating results for the second quarter of 2025, Dwayne L.

94 MW Solar Facility Holds Power Purchase Agreement with Constellation KITCHENER, ON , July 17, 2025 /PRNewswire/ -- Recurrent Energy, a subsidiary of Canadian Solar Inc. ("Canadian Solar") (NASDAQ: CSIQ) and a global developer, owner, and operator of solar and energy storage assets, announced today it has closed project financing and tax equity for Blue Moon Solar. U.S. Bank, through its subsidiary U.S. Bancorp Impact Finance, is providing both tax equity and construction financing for the project, totaling $260 million.

Approval Follows Successful Pre-IND Meeting with the U.S. FDA on iTOL-102, a Potential Cure for Type 1 diabetes that would circumvent the need for life-long immunosuppression drugs ZURICH , July 17, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system disorders, today announced that the Israel-U.S. Binational Industrial Research and Development Foundation (the "Bird Foundation") has approved another milestone-based funding payment to Kadimastem Ltd.

MINNEAPOLIS , July 17, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 6, 2025, at 8:00 a.m. CDT to review its fourth quarter and fiscal 2025 financial results.

it's been nearly three months since gold climbed past $3,500 an ounce to its highest price on record, but five key factors to emerge since the start of President Donald Trump's second term are likely to support prices in the months ahead.

SANTA ANA, Calif. , July 17, 2025 /PRNewswire/ -- Identiv, Inc. (NASDAQ: INVE), a global leader in RFID- and BLE-enabled Internet of Things (IoT) solutions, will hold a teleconference and webcast on Thursday, August 7, 2025, at 5:00 PM EDT to discuss its financial results for the second quarter ended June 30, 2025.

Miami, FL, July 17, 2025 (GLOBE NEWSWIRE) -- Tecnoglass, Inc. (NYSE: TGLS) ("Tecnoglass" or the "Company"), a leading producer of high-end aluminum and vinyl windows and architectural glass for the global residential and commercial end markets, today announced it will release financial results for the second quarter 2025 before the market opens on Thursday, August 7, 2025. Management will host a webcast and conference call that same day at 10:00 a.m. Eastern time to review the Company's results.

TORONTO, July 17, 2025 (GLOBE NEWSWIRE) -- Barrick Mining Corporation (NYSE:B)(TSX:ABX) will release its second quarter 2025 results before markets open on Monday, August 11, 2025 at approximately 6:00 AM EDT. President and CEO Mark Bristow will host a webcast to discuss the results at 11:00 AM EDT followed by a question-and-answer session with analysts.

China's central bank has been buying physical gold to add to its reserves for at least the last three years – and there's growing speculation that the country may be purchasing even more of the metal in secret as part of a strategy to reduce its reliance on the U.S. dollar.

HOLLISTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced a CEO succession plan under which John Duke will assume the role of President & CEO following the planned retirement of Jim Green, effective July 28, 2025. Jim Green will be retiring from his President, CEO & Chairman roles at Harvard Bioscience after more than 8 years as Chairman and 6 years as President & CEO.

CHICAGO, July 17, 2025 (GLOBE NEWSWIRE) -- Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) ("Chicago Atlantic" or the “Company”), a commercial mortgage real estate investment trust, announced details for the release of its results for the second quarter ended June 30, 2025.